JPRN-UMIN000012343已完成2 期
Phase II study of nab-paclitaxel for relapsed non-small cell lung cancer (NLCTG1302) - Phase II study of nab-PTX for relapsed NSCLC(NLCTG1302)
iigata Lung Cancer Treatment Group0 个研究点目标入组 65 人开始时间: 2013年11月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)History of paclitaxel treatment 2)Severe complications 1:Type 2 DM treated with insulin injection 2:Symptomatic congestive heart failure or unstable angina or problematic arrhythmia or history of acute myocardial infarction within one year 3:Interstitial pneumonia or active radiation pneumonia or drug-induced pneumonia 3)Problematic infection 4)History of active double cancer 5)Severe drug allergy 6)No intention to birth control 7)Unstable psychic disorder 8)Decision of ineligibility by a physician.
研究者
相似试验
已完成
不适用
Phase II Study of nab-paclitaxel in Treated Patients with Advanced Non-Small Cell Lung CancerTreated patients with advanced non-small cell lung cancerJPRN-UMIN000015841Tohoku Medical and Pharmaceutical University30
已完成
不适用
Phase II study of nab-paclitaxel in patients with previously treated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012114Osaka City General Hospital30
已完成
2 期
Phase 2 study of Nab-Paclitaxel for patients with previously treated EGFR wild-type non-small-cell lung cancer.on-small-cell lung cancerJPRN-UMIN000018233Shimane university hospital45
已完成
2 期
Phase II study of weekly nab-paclitaxel in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy.JPRN-UMIN000013390ational Hospital Organization Asahikawa Medical center40
已完成
2 期
Randomized phase II study of nab-Paclitaxel (nab-PTX) plus Carboplatin(CBDCA) followed by maintenance nab-PTX or TS-1 plus CBDCA followed by maintenance TS-1 as first-line treatment in patients with stage IIIB/IV squamous cell carcinoma of the lung.squamous cell carcinoma of the lungJPRN-UMIN000012903Internationanl University of Health and Welfare, Respiratory Disease center58